The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study
NCT06652555
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
ALK
NSCLC
Interventions
OTHER:
Group 1
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China